These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32669452)

  • 1. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
    Barbulescu A; Delcoigne B; Askling J; Frisell T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F; Yun H; Bernatsky S; Curtis JR
    Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
    Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
    Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
    Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D; Patil D; McDonald L; Patel V; Lobo F
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
    Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
    Curtis JR; Xie F; Chen L; Spettell C; McMahan RM; Fernandes J; Delzell E
    Arthritis Rheum; 2011 Feb; 63(2):346-51. PubMed ID: 20967860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
    Wadström H; Frisell T; Sparén P; Askling J;
    Ann Rheum Dis; 2016 Jul; 75(7):1272-8. PubMed ID: 26755797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
    Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
    Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.
    Závada J; Lunt M; Davies R; Low AS; Mercer LK; Galloway JB; Watson KD; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2014 Jan; 73(1):252-5. PubMed ID: 23644671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.